Lung Adenocarcinoma Treatment Market To Reach $11.18 Billion By 2030

Lung Adenocarcinoma Treatment Market Growth & Trends

The global lung adenocarcinoma treatment market size is anticipated to reach USD 11.18 billion by 2030 and is projected to grow at a CAGR of 10.68% during the forecast period, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms. 

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

 Request a free sample copy or view report summary: Lung Adenocarcinoma Treatment Market Report

Lung Adenocarcinoma Treatment Market Report Highlights

• On the basis of treatment, chemotherapy dominated the market in 2023. The advent of personalized medicine led to the development of targeted chemotherapy regimens tailored to specific genetic mutations found in lung adenocarcinoma patients, further enhancing treatment efficacy and patient outcomes.

• On the basis of end use, hospitals dominated the market with the largest revenue share of 64.34% in 2023. The increasing prevalence of lung adenocarcinoma globally has led to a higher demand for hospitalization, as patients require complex interventions such as chemotherapy, targeted therapy, and surgical procedures that can only be performed in a hospital setting.

Lung Adenocarcinoma Treatment Market Segmentation

Grand View Research has segmented the global lung adenocarcinoma treatment market on the basis of treatment, end-use and region:

Lung Adenocarcinoma Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Targeted Therapy

• Immunotherapy

• Radiation Therapy

• Other

Lung Adenocarcinoma Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Other

Lung Adenocarcinoma Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait 

List of Key Players in theLung Adenocarcinoma Treatment Market

• Pfizer

• AstraZeneca

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• Boehringer Ingelheim International GmbH

• Novartis AG

• Merck KGaA (EMD Serono)

• AbbVie Inc.

• Astellas Pharma Inc.

• F. Hoffmann-La Roche